Finoriq research workspace
Biodexa Pharmaceuticals Plc (BDRX) Historical Metrics
In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere. Review BDRX fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
- Company
- Biodexa Pharmaceuticals Plc (BDRX)
- Ticker
- BDRX
- Market Cap
- $1.5M
- Latest Price
- $2.00
- Industry
- Biotech & Pharma
Biodexa Pharmaceuticals Plc (BDRX) Current Valuation Metrics
Static valuation preview for Biodexa Pharmaceuticals Plc (BDRX). Market data retrieved 2026-07-08. Filing currency GBP.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -0.05% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -0.04% | Operating Cash Flow | TTM FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.